Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284–294. https://doi.org/10.1016/s1474-4422(21)00409-9

Article  CAS  PubMed  Google Scholar 

Cohen F, Yuan H, Silberstein SD (2022) Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs 36(3):341–358. https://doi.org/10.1007/s40259-022-00530-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Villar-Martinez MD, Goadsby PJ (2022) Pathophysiology and therapy of associated features of migraine. Cells 11(17):2767. https://doi.org/10.3390/cells11172767

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konstantinos S, Vikelis M, Rapoport A (2020) Acute care and treatment of migraine. J Neuroophthalmol 40(4):472–484

Article  PubMed  Google Scholar 

Diener HC (2020) The risks or lack thereof of migraine treatments in vascular disease. Headache 60(3):649–53. https://doi.org/10.1111/head.13749

Article  PubMed  Google Scholar 

Nisar A, Ahmed Z, Yuan H (2023) Novel therapeutic targets for migraine. Biomedicines. 11(2). https://doi.org/10.3390/biomedicines11020569

Liu J, Wang G, Dan Y, Liu X (2022) CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain 23(1):68. https://doi.org/10.1186/s10194-022-01435-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, Vélez C et al (2022) Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine—clinical considerations. Neurology 99(19):841–853. https://doi.org/10.1212/WNL.0000000000201332

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rissardo JP, Caprara ALF (2022) Gepants for acute and preventive migraine treatment: a narrative review. Brain Sci 12(12):1612. https://doi.org/10.3390/brainsci12121612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F (2022) Gepants—a long way to cure: a narrative review. Neurol Sci 43(9):5697–5708. https://doi.org/10.1007/s10072-022-06184-8

Article  PubMed  PubMed Central  Google Scholar 

Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ (2022) New generation Gepants: migraine acute and preventive medications. J Clin Med 11(6):1656. https://doi.org/10.3390/jcm11061656

Article  CAS  PubMed  PubMed Central  Google Scholar 

dos Santos JBR, da Silva MRR (2022) Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur J Pharmacol 922:174902. https://doi.org/10.1016/j.ejphar.2022.174902

Article  CAS  PubMed  Google Scholar 

Haghdoost F, Puledda F, Garcia-Azorin D, Huessler E-M, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023(4). https://doi.org/10.1177/03331024231159366

Lee S, Staatz CE, Han N, Baek IH (2022) Safety evaluation of oral calcitonin-gene–related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis. Eur J Clin Pharmacol 78(9):1365–76. https://doi.org/10.1007/s00228-022-03347-6

Article  CAS  PubMed  Google Scholar 

Baraldi C, Dagmar B, Paolo M, Pellesi L (2024) The preclinical discovery and development of Atogepant for migraine prophylaxis. Expert Opin Drug Discov 19(7):783–788. https://doi.org/10.1080/17460441.2024.2365379

Article  CAS  PubMed  Google Scholar 

Pellesi L, Budour J, Fadia B, Samah A-A, Paolo M, Xiao Z (2025) Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag 15(5):279–284. https://doi.org/10.1080/17581869.2025.2494494

Article  PubMed  Google Scholar 

Wells-Gatnik WD, Lanfranco P, Martelletti P (2024) Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert Rev Neurother 24(11):1107–1117. https://doi.org/10.1080/14737175.2024.2401558

Article  CAS  PubMed  Google Scholar 

Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H (2024) Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases. Front Pharmacol. 15. https://doi.org/10.3389/fphar.2024.1431562

Battini V, Carla C, Emilio C, Sessa M (2023) Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the food and drug administration adverse event reporting system. Expert Opin Drug Saf 22(11):1105–1112. https://doi.org/10.1080/14740338.2023.2223958

Article  PubMed  Google Scholar 

Hu J-L, Wu J-Y, Xu S, Qian S-Y, Jiang C, Zheng G-Q (2024) Post-marketing safety concerns with rimegepant based on a pharmacovigilance study. J Headache Pain 25(1):169. https://doi.org/10.1186/s10194-024-01858-4

Article  PubMed  PubMed Central  Google Scholar 

Cao B, Shanshan G, Zhisen S, Yuna Z, Yiming S, Chen H (2024) Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system. Expert Opin Drug Saf 23(3):297–303. https://doi.org/10.1080/14740338.2023.2251390

Article  CAS  PubMed  Google Scholar 

Zhang Y, Shengzhu S, Wang Y (2024) Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis. Expert Opinion on Drug Safety. 1–7. https://doi.org/10.1080/14740338.2024.2393268

Wen H, Yitian D, Chen F (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant. Expert Opin Drug Saf. 1–8. https://doi.org/10.1080/14740338.2024.2377347

Pan H, Lin S (2024) A real-world adverse events study of rimegepant from the FAERS database. Expert Opin Drug Saf. 1–6. https://doi.org/10.1080/14740338.2024.2418319

Wong CK, Ho SS, Saini B, Hibbs DE, Fois RA (2015) Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants. Pharmacoepidemiol Drug Saf 24(7):731–737. https://doi.org/10.1002/pds.3805

Article  PubMed  Google Scholar 

Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10(7):796–803. https://doi.org/10.7150/ijms.6048

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarangdhar M, Tabar S, Schmidt C, Kushwaha A, Shah K, Dahlquist JE et al (2016) Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 34(7):697–700. https://doi.org/10.1038/nbt.3623

Article  CAS  PubMed  Google Scholar 

Yang X, Zheng X, Zhang M, Huang J, Huang P, Wang J (2024) Drug-induced gynecomastia: data mining and analysis of the FDA adverse event reporting system database. Clin Epidemiol 16:617–630. https://doi.org/10.2147/clep.S470959

Article  PubMed  PubMed Central  Google Scholar 

van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3–10. https://doi.org/10.1002/pds.668

Article  CAS  PubMed  Google Scholar 

Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483–486. https://doi.org/10.1002/pds.677

Article  CAS  PubMed  Google Scholar 

Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315–321. https://doi.org/10.1007/s002280050466

Article  CAS  PubMed  Google Scholar 

Dias P, Penedones A, Alves C, Ribeiro CF, Marques FB (2015) The role of disproportionality analysis of pharmacovigilance databases in safety regulatory actions: a systematic review. Curr Drug Saf 10(3):234–250. https://doi.org/10.2174/1574886310666150729112903

Article